Institute of Biochemistry
Faculty of Medicine
University of Ljubljana

Vrazov trg 2
SI 1000, Ljubljana
Slovenia

Tel: +386-1-543-7672
Fax: +386-1-543-7641

Laboratory for translational molecular endocrinology

RESEARCH I  MEMBERS I  FUNDING I  THESES I  AWARDS I  PUBLICATIONS I  COLLABORATIONS I  EQUIPMENT I  NEWS

FUNDING

Slovenian Research Agency programme J3-0499 »Translational molecular endocrinology for women's health«, 1. 1. 2024 – 31. 12. 2027;

Slovenian Research Agency grant Z3-4522 »Establishment and characterization of a novel human stromal cell line of peritoneal endometriosis«, 1. 10. 2022 – 31. 9. 2025;

Slovenian Research Agency grant L4-4565 »Development of new in vitro 3D mono and co-culture models of high grade serous ovarian cancer for drug testing and development of new targeted and stratified therapies«, 1. 10. 2022 – 31. 9. 2025;

MSCA RISE project »Translational Research on Endometriosis« – TRENDO, 1.8. 2021 – 31.7. 2025;

Slovenian Research Agency grant N1-0234 (Leading agency NKFIH) »Modern chemical and biochemical approaches towards identification of anticancer and drug resistance preventing steroidal agents«, 1. 1. 2022 – 31. 10. 2025;

CELSA project »Targeting AKR1Cs to reverse chemoresistance in ovarian cancer«, 1. 10. 2024 – 30. 9. 2026;

Slovenian Research Agency grant J3-3069 »The importance of various surgical techniques on the molecular mechanisms of gynecologic cancer recurrence«, 1. 10. 2021 – 30. 9. 2024 (P.I. Prof. Dr. Iztok Takač);

Slovenian Research Agency grant J3-2535 »The importance of androgens in hormone dependent diseases: impact on diagnostics and therapy«, 1. 9. 2020 – 31. 8. 2023;

Slovenian Research Agency grant J3-1755 »Biomarkers of endometriosis: transcriptomics and proteomics approach«, 1. 7. 2019 – 30. 6. 2022;

ERA-NET Transcan 2 project »Biomarkers for diagnosis and prognosis of endometrial carcinoma«, BioEndoCar 1. 4. 2018 – 31. 3. 2022;

Slovenian Research Agency grant N1-0066 (Leading agency NKFIH) »Development of novel estrone derivatives for targeted intracrine modulation of estrogen biosynthesis and transport«, 1. 11. 2017 – 31. 10. 2021;

Slovenian Research Agency grant J3-8212 »The importance of intracrine estrogen action in hormone dependent diseases – impact on therapy«, 1. 6. 2017 – 31. 5. 2020;

Slovenian Research Agency grant J3-8206 »The effects of weight loss on gene expression in endometrium of infertile patients with PCOS and obesity«, 1. 6. 2017 – 31. 5. 2020 (P.I. Prof. Dr. Eda Vrtačnik-Bokal);

Slovenian Research Agency bilateral grant BI-DE/18-19-004 »Progesterone metabolites as potential biomarkers«, 1. 1. 2018 – 31. 12. 2019.

Slovenian Research Agency grant J3-6799 »Biomarkers of endometriosis: proteomics and metabolomics approach«, 1. 7. 2014 – 30. 6. 2017;

Slovenian Research Agency grant J3-5510 »The role of progesterone metabolites in hormone dependent diseases«, 1. 8. 2013 – 31. 7. 2016;

Helmholtz Zentrum Munchen Grant G-508200-016 »Metabolites as Diagnostic Biomarkers of Endometriosis«, 1. 1. 2015 – 31. 12. 2016;

ICGEB CRP grant »The role of progesterone metabolism in endometriosis«, 1. 7. 2012 – 30. 6. 2015;

Slovenian Research Agency grant J3-4135 »Molecular basis of endometriosis and endometrial cancer-metabolomics approach«, 1. 7. 2011 – 30. 6. 2014;

Industrial grant »Expression analysis of drug transporters with the use of PCR arrays« Lek Pharmaceutical Company Ljubljana, Slovenia, 1. 2. 2011 – 30. 11. 2011;

Slovenian Research Agency grant J3-9448 »Molecular basis of endometriosis and endometrial cancer«, 1. 7. 2007 – 30. 6. 2010;

Industrial grant »Validation of 17beta-HSD type 1 for endometriosis therapy«, Bayer Schering Pharma, Berlin, Germany, Support Grant, 13. 8. 2009 – 13. 8. 2010;

Industrial grant »Validation of AKR1C1 for endometriosis therapy«, Bayer Schering Pharma, Berlin, Germany, Focus Grant, 18. 11. 2009 – 18. 11. 2010;

Industrial grant »Expression analysis of drug transporters with the use of PCR arrays« Lek Pharmaceutical Company Ljubljana, 1. 6. 2010 – 30. 11. 2010;

Industrial grant »Evaluation of inhibitory potency of dydrogesterone, dihydrodydrogesterone and progesterone against the recombinant AKR1C3 and 17beta-HSD type 3« Solvay Pharmaceuticals GmbH. Hannover, Germany, 1. 11. 2008 – 1. 5. 2009;

Slovenian Research Agency grant L3-6226 »Endometriosis and endometrial cancer: preparation of in vitro model and identification of novel drug targets«, 1. 2. 2004 – 30. 1. 2007;

Industrial grant »Gene expression analysis of human endometrial and endometriotic tissue«, Solvay Pharmaceuticals GmbH. Hannover, Germany, 1. 9. 2004 – 31. 8. 2005;

NATO CLG grant »Role of 17beta-Hydroxysteroid Dehydrogenases in Endometriosis and Endometrial Cancer«, 11. 8. 2003 – 11. 8. 2005;

NATO CLG grant »Analysis of Steroid Signaling Pathway in Fungi: Role of 17beta-Hydroxysteroid Dehydrogenase«, 1. 11. 1999 – 30. 10. 2001.